SCYNEXIS (SCYX) 10-Q 8 May 18 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 01, 2018
Document And Entity Information [Abstract]
Entity Registrant Name	SCYNEXIS INC
Trading Symbol	SCYX
Entity Central Index Key	1,178,253
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		46,843,441

Unaudited Condensed Balance She

Unaudited Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 27,223	$ 11,469
Short-term investments	36,477	32,424
Prepaid expenses and other current assets	645	1,067
Total current assets	64,345	44,960
Other assets	585	576
Deferred offering costs	230	314
Restricted cash	328	0
Total assets	65,488	45,850
Current liabilities:
Accounts payable	3,331	3,833
Accrued expenses	937	1,705
Deferred revenue, current portion	257	257
Loan payable, current portion	3,599	4,349
Total current liabilities	10,852	10,144
Warrant liability	2,728	0
Deferred revenue, non-current	57	121
Warrant liabilities	6,571	3,872
Loan payable, long term	11,164	10,303
Total liabilities	28,644	24,440
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 5,000,000 shares as of March 31, 2018 and December 31, 2017; 0 shares issued and outstanding as of March 31, 2018 and December 31, 2017	0	0
Common stock, $0.001 par value, 125,000,000 shares authorized as of March 31, 2018, and December 31, 2017; 46,843,441 and 28,971,651 shares issued and outstanding as of March 31, 2018, and December 31, 2017, respectively	47	29
Additional paid-in capital	246,049	226,631
Accumulated deficit	(209,252)	(205,250)
Total stockholders’ equity	36,844	21,410
Total liabilities and stockholders’ equity	$ 65,488	$ 45,850

Unaudited Condensed Balance Sh3

Unaudited Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	46,843,441	28,971,651
Common stock, shares outstanding (in shares)	46,843,441	28,971,651

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenue	$ 64	$ 64
Operating expenses:
Research and development, net	5,326	4,020
Selling, general and administrative	1,971	2,060
Total operating expenses	7,297	6,080
Loss from operations	(7,233)	(6,016)
Other (income) expense:
Amortization of debt discount	111	100
Interest income	(167)	(69)
Interest expense	379	345
Warrant liabilities fair value adjustment	(3,554)	(1,523)
Total other income	(3,231)	(1,147)
Net loss	(4,002)	(4,869)
Warrant liability fair value adjustment		(1,523)
Net loss attributable to common stockholders - diluted	$ (4,002)	$ (6,392)
Net loss per share attributable to common stockholders - basic
Net loss per share - basic	$ (0.12)	$ (0.19)
Net loss per share attributable to common stockholders - diluted
Net loss per share - diluted	$ (0.12)	$ (0.25)
Weighted average common shares outstanding
Basic	33,579,025	25,364,429
Diluted	33,579,025	25,562,027

Unaudited Condensed Statements5

Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net loss	$ (4,002)	$ (4,869)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1	1
Stock-based compensation expense	425	396
Accretion/amortization of investment discount/premium	(58)	100
Amortization of debt discount	111	100
Change in fair value of warrant liabilities	(3,554)	(1,523)
Changes in deferred rent	(4)	(5)
Changes in operating assets and liabilities:
Prepaid expenses, other assets, and deferred costs	422	(549)
Accounts payable and accrued expenses	(1,496)	(359)
Deferred revenue	(64)	(64)
Net cash used in operating activities	(8,219)	(6,772)
Cash flows from investing activities:
Maturities of investments	11,980	6,000
Purchases of property and equipment	(10)	(2)
Purchase of investments	(15,975)	(18,161)
Net cash used in investing activities	(4,005)	(12,163)
Cash flows from financing activities:
Proceeds from common stock issued	30,192	3,277
Payments of deferred offering costs and underwriting discounts and commissions	(1,906)	(108)
Proceeds from employee stock purchase plan issuance	20	18
Net cash provided by financing activities	28,306	3,187
Net increase in cash, cash equivalents, and restricted cash	16,082	(15,748)
Cash, cash equivalents, and restricted cash at beginning of period	11,469	35,656
Cash, cash equivalents, and restricted cash at end of period	27,551	19,908
Supplemental cash flow information:
Cash paid for interest	379	345
Cash received for interest	128	60
Noncash financing and investing activities:
Deferred offering costs included in accounts payable and accrued expenses	224
Deferred offering costs reclassified to additional-paid-in capital	$ 84	$ 10

Description of Business and Bas

Description of Business and Basis of Preparation	3 Months Ended
	Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business and Basis of Preparation	1. Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The Company is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous triterpenoid antifungal family for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The Company has incurred losses and negative cash flows from operations since its initial public offering ("IPO") in May 2014 and expects to continue to incur losses. The Company's liquidity over the next 12 months could be materially affected by, among other things: its ability to raise capital through equity offerings, debt financings, other non-dilutive third-party funding (e.g., grants), strategic alliances and licensing or collaboration arrangements; key SCY-078 development and regulatory events; costs related to its development of SCY-078; and other factors. Shelf Registration Filing On October 30, 2015, the Company filed a shelf registration statement on Form S-3 with the SEC, which was declared effective on November 16, 2015. The registration statement contained two prospectuses: • a base prospectus which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $150.0 million of the Company's common stock, preferred stock, debt securities and warrants, including common stock or preferred stock issuable upon conversion of debt securities, common stock issuable upon conversion of preferred stock, or common stock, preferred stock or debt securities issuable upon the exercise of warrants (the "Shelf Registration"), and • a prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $40.0 million of the Company's common stock that may be issued and sold under a Controlled Equity Offering Sales Agreement SM The common stock that may be offered, issued and sold by the Company under the Sales Agreement is included in the $150.0 million of securities that may be offered, issued and sold by the Company under the base prospectus. Upon termination of the Sales Agreement with Cantor, any portion of the $40.0 million included in the Sales Agreement that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement. In addition, the Company has conducted two offerings of common stock and warrants under the registration statement, including $52.5 million relating to the offer and sale of shares issuable pursuant to the warrants sold. As a result, as of March 31, 2018, the remaining amount of common stock and other allowable securities to be offered under the Sales Agreement and Shelf Registration (including any unsold portion of the $40.0 million included in the Sales Agreement but excluding the sale of shares pursuant to the outstanding warrants) was $23.9 million and $28.2 million, respectively. The Shelf Registration will expire on November 16, 2018. The Company intends to file a new shelf registration on Form S-3 with the SEC prior to the expiration of the Shelf Registration. March 2018 Public Offering On March 8, 2018, the Company completed a public offering (the "March 2018 Public Offering") of its common stock and warrants pursuant to the Company's effective Shelf Registration. The Company sold an aggregate of 17,751,500 shares of the Company’s common stock and warrants to purchase up to 21,301,800 shares of the Company’s common stock at a public offering price of $1.69 per share. Net proceeds from the March 2018 Public Offering were approximately $27.9 million, after deducting the underwriting discount and estimated offering expenses. See Note 8 for further details. Unaudited Interim Financial Information The accompanying unaudited financial statements and notes have been prepared in accordance with accounting principles generally accepted in the United States, or US GAAP, as contained in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (the “Codification” or “ASC”) for interim financial information. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the results of operations, financial position, and cash flows. The results of operations for the three months ended March 31, 2018, are not necessarily indicative of the results for the full year or the results for any future periods. These interim financial statements should be read in conjunction with the financial statements and notes set forth in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC") on March 13, 2018. Use of Estimates The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates include: determination of the fair value of stock-based compensation grants

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents held with one bank which exceed FDIC insured limits and certain short-term investments. Ongoing credit evaluations of the customer’s financial condition are performed and independent credit ratings for the associated counterparties are reviewed by the Company and collateral is not required. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any losses in such account. Cash, Cash Equivalents, and Restricted Cash The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents. The Company's cash and cash equivalents include cash on deposit and a money market fund. The Company reported cash, cash equivalents, and restricted cash of $27.6 million as of March 31, 2018. See Note 7 for further details on the nature of the restricted cash. Short-Term Investments The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment. Any impairment that is not deemed to be temporary is recognized in the period identified. Deferred Offering Costs Deferred offering costs are expenses directly related to the Form S-3 filed with the SEC on October 30, 2015 and declared effective on November 16, 2015. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the Shelf Registration. Deferred costs associated with the Shelf Registration are reclassified to additional paid in capital on a pro-rata basis when the Company completes offerings under the Shelf Registration, with any remaining deferred offering costs to be charged to the results of operations at the end of the three-year life of the Shelf Registration. Warrant Liabilities On June 21, 2016, the Company sold an aggregate of 9,375,000 shares of common stock and warrants (the “June 2016 Public Offering”) to purchase up to 4,218,750 shares of the Company's common stock under the Shelf Registration at a public offering price of $2.40 per share of common stock sold. On March 8, 2018, the Company sold 17,751,500 shares of its common stock and warrants to purchase up to 21,301,800 shares of the Company’s common stock under the Shelf Registration at a public offering price of $1.69 per share of common stock sold. The Company accounted for these warrants as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying statements of operation. See Note 8 for further details. Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss. Revenue Recognition and Deferred Revenue The Company has entered into arrangements involving the sale or license of intellectual property and the provision of other services. When entering into any arrangement involving the sale or license of intellectual property rights and other services, the Company determines whether the arrangement is subject to accounting guidance in ASC 606, Revenue from Contracts with Customers Collaborative Arrangements Analyzing the arrangement to identify performance obligations requires the use of judgment. In arrangements that include the sale or license of intellectual property and other promised services, the Company first identifies if the licenses are distinct from the other promises in the arrangement. If the license is not distinct, the license is combined with other services into a single performance obligation. Factors that are considered in evaluating whether a license is distinct from other promised services include, for example, whether the counterparty can benefit from the license without the promised service on its own or with other readily available resources and whether the promised service is expected to significantly modify or customize the intellectual property. The Company classifies non-refundable upfront payments, milestone payments and royalties received for the sale or license of intellectual property as revenues within its statements of operations because the Company views such activities as being central to its business operations. For the sale of intellectual property that is distinct, fixed consideration and variable consideration are included in the transaction price and recognized in revenue immediately to the extent that it is probable that there would not be a significant reversal of cumulative revenue in the future. For the license of intellectual property that is distinct, fixed and variable consideration (to the extent there will not be a significant reversal in the future) are also recognized immediately in income, except for consideration received in the form of royalty or sales-based milestones, which is recorded when the customer’s subsequent sales or usages occur. If the sale or license of intellectual property is not distinct, revenue is deferred and recognized over the estimated period of the Company’s combined performance obligation. For contractual arrangements that meet the definition of a collaborative arrangement under Topic 808, consideration received for any units-of-account that are outside the scope of Topic 606 are recognized in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014 (the “R-Pharm Agreement”), is a collaborative arrangement pursuant to Topic 808. The Company received a non-refundable upfront payment of $1.5 million from R-Pharm in August 2013 which is being recognized over the estimated relationship period of 70 months for the combined performance obligation that includes the license of intellectual property and the participation on a joint steering committee. The Company recognized revenue from this upfront payment of $0.1 million for the three months ended March 31, 2018 and 2017. The Company is entitled to receive other payments under the R-Pharm Agreement including development and sales-based milestones and royalties; however, the variable consideration was fully constrained as of March 31, 2018. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $0.3 million as of March 31, 2018 and December 31, 2017, which are presented in prepaid expenses and other current assets in the accompanying balance sheets. In July 2016, the Company entered into an Asset Purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the Asset Purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized. For the three months ended March 31, 2018, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained as of March 31, 2018. Additionally, in October 2014 we entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds. The Company is entitled to receive potential milestones and royalties from Waterstone and for the three months ended March 31, 2018, there was no revenue recognized by the Company associated with this agreement. Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Information about the Company’s gross research and development expenses and the reimbursements due under the collaboration arrangement with R-Pharm for the three months ended March 31, 2018 and 2017, is presented as follows (in thousands): Three Months Ended March 31, 2018 2017 Research and development expense, gross $ 5,326 $ 4,039 Less: Reimbursement of research and development expense — 19 Research and development expense, net of reimbursements $ 5,326 $ 4,020 Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. Amortization of Debt Discount The Company's term loan in the amount of $15.0 million (the “Term Loan”) with Solar Capital Ltd. (“Solar”) is recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the Term Loan (Note 8). The resulting debt discount is being amortized over the term of the Term Loan using the straight-line method, which approximates the effective interest method, and the amortization of debt discount is included in the accompanying statements of operations. Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. Certain modifications made to an outstanding incentive stock option award at any time after the initial grant dates which are considered to be “material modifications”, as defined within the Internal Revenue Code, may result in the affected award being recharacterized as a non-statutory stock option. The effects of any recharacterization modification for purposes of income tax accounting are recognized on a prospective basis. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the award is recorded as expense over the requisite service periods and the Company recognizes forfeitures as they occur in the period. Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. March 31, 2018 2017 Warrants to purchase Series C-1 Preferred 14,033 14,033 Warrants to purchase common stock associated with Loan Agreement 122,435 122,435 Warrants to purchase common stock associated with June 2016 Public Offering 4,218,750 — Warrants to purchase common stock associated with March 2018 Public Offering - Series 1 13,313,625 — Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 7,988,175 — Stock options 4,152,734 2,770,029 Effect of Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases, or ASU 2016-02. The new guidance requires lessees to recognize the assets and liabilities arising from leases on the balance sheet. For public companies, ASU 2016-02 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the impact that the implementation of ASU 2016-02 will have on the Company’s financial statements.

Short-term Investments

Short-term Investments	3 Months Ended
	Mar. 31, 2018
Investments Debt And Equity Securities [Abstract]
Short-term Investments	3. Short-term Investments The following table summarizes the held-to-maturity securities held at March 31, 2018 (in thousands): Amortized Cost Unrealized Gains Unrealized Losses Fair Value As of March 31, 2018 U.S. government securities $ 10,990 $ 5 $ (6 ) $ 10,989 Commercial paper 7,487 — — 7,487 Overnight repurchase agreement 18,000 — — 18,000 Total short-term investments $ 36,477 $ 5 $ (6 ) $ 36,476 All held-to-maturity short-term investments at March 31, 2018 will mature in less than one year. The gross unrealized gains and losses for the Company's commercial paper and overnight repurchase agreement are not significant. The Company carries short-term investments at amortized cost. The fair value of the short-term investments is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2018
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2018 December 31, 2017 Prepaid SCY-078 development services $ 48 $ 384 Prepaid insurance 96 279 Other prepaid expenses 158 62 Other receivable due from R-Pharm 251 251 Other current assets 92 91 Total prepaid expenses and other current assets $ 645 $ 1,067

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2018
Payables And Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consisted of the following (in thousands): March 31, 2018 December 31, 2017 Accrued research and development expenses $ 355 $ 609 Accrued employee bonus compensation 261 763 Employee withholdings 32 29 Other accrued expenses 289 304 Total accrued expenses $ 937 $ 1,705

Borrowings

Borrowings	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Borrowings	6. Borrowings On September 30, 2016, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Solar, in its capacity as administrative and collateral agent and as lender. Pursuant to the Loan Agreement, Solar is providing the Company with a 48-month secured Term Loan in the amount of $15.0 million. The Term Loan bears interest at a floating rate equal to the LIBOR rate in effect plus 8.49% and the Company was required to make interest-only payments on the Term Loan beginning November 1, 2016 through March 1, 2018. Beginning April 1, 2018 (the “Amortization Date”), the Company was required to make monthly payments of interest plus equal monthly principal payments from April 1, 2018 through September 30, 2020 (the “Maturity Date”). In March 2018, the Loan Agreement was amended and the Company is required to make monthly payments of interest plus equal monthly principal payments from October 1, 2018 through the Maturity Date of the Term Loan. The final fee payable at the Maturity Date was also increased by thirty thousand dollars. The Company will continue to pay interest-only payments through October 1, 2018. Except as described above, all other terms and provisions of the Loan Agreement remain in full force and effect. The ultimate term of the Term Loan was not extended and the equal monthly payments of principal will be calculated based on the remaining term of the Term Loan. The obligations under the Loan Agreement are secured by a lien on substantially all assets of the Company other than its intellectual property, which is subject to a negative pledge. The Loan Agreement contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, reporting requirements and compliance with applicable laws and regulations. Further, the Loan Agreement contains customary negative covenants limiting the ability of the Company, among other things, to incur debt, grant liens, make investments, make acquisitions, make certain restricted payments and sell assets, subject to certain exceptions, and maintain certain minimum liquidity requirements. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding principal and accrued but unpaid interest under the Loan Agreement immediately due and payable and may exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement include payment defaults, cross defaults with certain other agreements, breaches of covenants or representations and warranties, the occurrence of a material adverse effect and certain bankruptcy events. The Company has the right to prepay the Term Loan in whole at any time and the Loan Agreement contains customary prepayment and closing fees. Pursuant to the Loan Agreement, on September 30, 2016 (the "Closing Date"), the Company issued to Solar a warrant (the “Solar Warrant”) to purchase an aggregate of up to 122,435 shares of the Company’s common stock at an exercise price of $3.6754 per share. The Solar Warrant will expire five years from the date of the grant. The Solar Warrant is classified as equity and was recorded at its relative fair value at issuance in the stockholders' equity section of the balance sheet (See Note 8). Future principal debt payments on the currently outstanding Term Loan payable as of March 31, 2018 are as follows (in thousands): 2018 $ 1,875 2019 7,500 2020 5,625 Total principal payments 15,000 Final fee due at maturity 780 Total principal and final fee payment 15,780 Unamortized discount and debt issuance costs (1,017 ) Less current portion (3,599 ) Loan payable, long term $ 11,164

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Leases The Company leases its headquarters facilities under a long-term non-cancelable operating lease. On July 13, 2015, the Company entered into a sublease (the "Sublease") that became effective July 22, 2015, to sublet certain premises consisting of 10,141 square feet of space (the "Subleased Premises") located at 101 Hudson Street, Jersey City, New Jersey from Optimer Pharmaceuticals, Inc. The term of the Sublease commenced on August 1, 2015 (the "Commencement Date") and is scheduled to expire on July 30, 2018. No base rent was due under the Sublease until one month after the Commencement Date. Under the Sublease, the Company is obligated to pay monthly base rent of approximately twenty-five thousand dollars per month, which amount increases by 3% annually on each anniversary of the Commencement Date. In addition, the Company was required to fund a security deposit with the sublandlord in the amount of $0.1 million. On March 1, 2018, the Company entered into a long-term lease agreement for approximately 19,275 square feet of office space in Jersey City, New Jersey. The lease term is eleven years from the commencement date which is the later of July 1, 2018 or the substantial completion of certain improvements to the leased space, with total lease payments of $7.3 million over the lease term. The Company has the option to renew for two consecutive five-year periods from the end of the first term. Under the lease, the Company must furnish a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease. The security deposit is classified as restricted cash in the accompanying balance sheets . The Company’s lease is for a fully built-out space, which the landlord is currently renovating at its own cost of up to $1.3 million. Rent expense was approximately $0.1 million for the three months ended March 31, 2018 and 2017. Future minimum lease payments for all operating leases as of March 31, 2018 are as follows (in thousands): 2018 $ 510 2019 498 2020 508 2021 518 2022 529 Thereafter 4,919 Total $ 7,482 License Arrangement with Potential Future Expenditures As of March 31, 2018, the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, that involves potential future expenditures. Under the license arrangement, the Company exclusively licensed from Merck its rights to SCY-078 in the field of human health. SCY-078 is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19.0 million upon occurrence of specific events, including initiation of a Phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalty percentages are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that deferred the remittance of a milestone payment due to Merck, such that no amount would be due upon initiation of the first Phase 2 clinical trial of a product containing the SCY-078 compound (the "Deferred Milestone"). The amendment also increased, in an amount equal to the Deferred Milestone, the milestone payment that would be due upon initiation of the first Phase 3 clinical trial of a product containing the SCY-078 compound. In December 2016 and January 2018, the Company entered into second and third amendments, respectively, to the license agreement with Merck which clarified what would constitute the initiation of a Phase 3 clinical trial for the purpose of milestone payment. Except as described above, all other terms and provisions of the license agreement remain in full force and effect. The Company has two additional licensing agreements for other compounds that could require it to make payments of up to $2.3 million upon achievement of certain milestones by the Company. Clinical Development Arrangements The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice. Legal Proceeding On March 8, 2017, a purported stockholder class action lawsuit was filed in the United States District Court for the District of New Jersey against the Company and certain of its current and former officers, captioned Gibson v. Scynexis, Inc., et al. The action was filed on behalf of a putative class of all persons who purchased or otherwise acquired the Company's securities (1) pursuant or traceable to the Company's IPO, or (2) on the open market between May 2, 2014, and March 2, 2017. It asserts claims for violation of Sections 11 and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint seeks, among other things, compensatory damages and attorneys’ fees and costs on behalf of the putative class. The Company believes that the claims lack merit and intends to defend the litigation vigorously. ASC Topic 450, Contingencies

Stockholder's Equity

Stockholder's Equity	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Stockholder's Equity	8. Stockholder's Equity Authorized, Issued, and Outstanding Common Stock The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares as of March 31, 2018, and December 31, 2017; 46,843,441 and 28,971,651 shares were issued and outstanding at March 31, 2018, and December 31, 2017, respectively. The following table summarizes common stock share activity for the three months ended March 31, 2018 (dollars in thousands): Shares of Common Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders' Equity Balance, December 31, 2017 28,971,651 $ 29 $ 226,631 $ (205,250 ) $ 21,410 Net loss — — — (4,002 ) (4,002 ) Stock-based compensation expense — — 425 — 425 Common stock issued through employee stock purchase plan 13,591 — 20 — 20 Common stock issued under Shelf Registration, net of expenses 17,852,193 18 18,980 — 18,998 Common stock issued for vested restricted stock units 6,006 — (7 ) — (7 ) Balance, March 31, 2018 46,843,441 $ 47 $ 246,049 $ (209,252 ) $ 36,844 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: March 31, 2018 December 31, 2017 Outstanding stock options 4,152,734 3,075,994 Outstanding Series C-1 Preferred warrants 14,033 14,033 Warrants to purchase common stock associated with June 2016 Public Offering 4,218,750 4,218,750 Warrants to purchase common stock associated with March 2018 Public Offering - Series 1 13,313,625 — Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 7,988,175 — Warrants to purchase common stock associated with Loan Agreement 122,435 122,435 For possible future issuance under 2014 Equity Incentive Plan (Note 9) 528,197 492,382 For possible future issuance under Employee Stock Purchase Plan (Note 9) 99,437 83,617 For possible future issuance under 2015 Inducement Plan (Note 9) 5,000 5,000 Total common shares reserved for future issuance 30,442,386 8,012,211 Warrants Associated with Convertible Preferred Stock Issuances In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Preferred Stock, which converted into the right to purchase 14,033 shares of common stock in connection with the Company's IPO; however, the Company refers to these warrants as its Series C-1 Preferred warrants. The Series C-1 Preferred warrants were issued in conjunction with a loan financing agreement with an original exercise price of $3.25 per share of Series C-1 Preferred, which converted into an exercise price of $45.61 per share of common stock in connection with the Company's IPO. These warrants remain outstanding as of March 31, 2018 and will expire on May 7, 2019, which is the five year anniversary of the Company's IPO. The fair value at the date of grant for these instruments was $0.5 million, which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. As of March 31, 2018 and December 31, 2017, the fair value of the warrant derivative liability was zero. Warrants Associated with June 2016 and March 2018 Public Offerings On June 21, 2016, the Company completed the June 2016 Public Offering of its common stock and warrants pursuant to the Company's effective Shelf Registration. Each purchaser received a warrant to purchase 0.45 of a share for each share purchased in the June 2016 Public Offering. There is not expected to be any trading market for the warrants. Each warrant was exercisable immediately upon issuance, will expire five years from the date of issuance, and has an exercise price of $3.00 per share. On March 8, 2018, the Company completed the March 2018 Public Offering and sold 17,751,500 shares of its common stock and warrants to purchase up to 21,301,800 shares of the Company’s common stock. Each purchaser received a warrant to purchase 0.75 of a share of common stock (the “Series 1 warrants”) and 0.45 of a share of common stock (the “Series 2 warrants”) for each share purchased in the March 2018 Public Offering. The Series 1 warrants to purchase in the aggregate up to 13,313,625 shares of common stock have a 53-week term and an exercise price of $1.85 per share, and the Series 2 warrants to purchase in the aggregate up to 7,988,175 shares of common stock have a five-year term and an exercise price of $2.00 per share. There is not expected to be any market for the warrants and each warrant is exercisable immediately upon issuance, subject to certain limitations on beneficial ownership. The warrants contain a provision where the warrant holder has the option to receive cash, equal to the Black-Scholes fair value of the remaining unexercised portion of the warrant, as cash settlement in the event that there is a fundamental transaction (contractually defined to include various merger, acquisition or stock transfer activities). Due to this provision, ASC 480, Distinguishing Liabilities from Equity, Warrant Associated with Loan Agreement Pursuant to the Loan Agreement, on the Closing Date the Company issued to Solar the Solar Warrant to purchase an aggregate of up to 122,435 shares of the Company’s common stock at an exercise price of $3.6754 per share. The Solar Warrant will expire five years from the date of the grant. The Solar Warrant was classified as equity and recorded at its relative fair value at issuance in the stockholders' equity section of the balance sheet.

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	9. Stock-based Compensation 2009 Stock Option Plan The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire 10 years from the date of grant. 2014 Equity Incentive Plan In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan, as amended on June 18, 2014 and February 25, 2015, is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. Under the 2014 Plan, after giving effect to the increases to the share reserve approved by the Company’s stockholders in September 2014, and June 2015, but excluding the automatic increases discussed below, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 1,122,731 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1st of each year, for a period of not more than 10 years, commencing on January 1, 2015, and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31st of the preceding calendar year. The board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. Pursuant to the terms of the 2014 Plan, on January 1, 2018 and 2017, the Company automatically added 1,158,866 and 984,376 shares to the total number shares of common stock available for future issuance under the 2014 Plan, respectively. As of March 31, 2018, there were 528,197 shares of common stock available for future issuance under the 2014 Plan. 2015 Inducement Plan On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan, or the 2015 Plan. The 2015 Plan has a share reserve covering 450,000 shares of common stock. During the three months ended March 31, 2018, there were no grants of the Company's common stock under the 2015 Inducement Plan. As of March 31, 2018, there were 5,000 shares of common stock available for future issuance under the 2015 Plan. The activity for the 2009 Stock Option Plan, 2014 Plan and 2015 Plan for the three months ended March 31, 2018, is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value ($000) Outstanding — January 1, 2018 3,075,994 $ 5.59 7.23 $ 151 Granted 1,111,470 $ 1.76 Exercised — $ — Forfeited/Cancelled (34,730 ) $ 4.53 Outstanding — March 31, 2018 4,152,734 $ 4.57 7.68 $ — Exercisable — March 31, 2018 1,859,894 $ 6.73 5.87 $ — Vested or expected to vest — March 31, 2018 4,152,734 $ 4.57 7.68 $ — Restricted stock unit ("RSU") activity under the 2014 Plan for the three months ended March 31, 2018, is summarized as follows: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2017 64,365 $ 2.70 Granted 51,550 $ 1.69 Vested (9,701 ) $ 3.11 Forfeited/Cancelled (5,239 ) $ 3.02 Non-vested at March 31, 2018 100,975 $ 2.13 The fair value of RSUs is based on the market price of the Company's common stock on the date of grant. RSUs are only issued to non-executive employees and vest 25% annually over a four-year period from the date of grant. Upon vesting, the RSUs are net share settled to cover the required withholding tax with the remaining shares issued to the holder. The Company recognizes compensation expense for such awards ratably over the corresponding vesting period. 2014 Employee Stock Purchase Plan In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014. The purpose of the ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. In the three months ended March 31, 2018, the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares pursuant to the terms of the ESPP and the Company issued 13,591 shares of common stock under the ESPP. During the three months ended March 31, 2017, the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares pursuant to the terms of the ESPP and the Company issued 7,667 shares of common stock under the ESPP. As of March 31, 2018, there were 99,437 shares of common stock available for future issuance under the ESPP. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, the 2015 Plan, and the ESPP was $0.4 million for the three months ended March 31, 2018 and 2017. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was zero for the three months ended March 31, 2018 and 2017. Cash received from options exercised was zero for the three months ended March 31, 2018, and 2017. Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands): Three Months Ended March 31, 2018 2017 Research and development $ 108 $ 94 Selling, general and administrative 317 302 Total $ 425 $ 396

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	10. Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period, pursuant to the policy described in Note 2. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of March 31, 2018 and December 31, 2017 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2017 Cash on deposit $ 1,316 $ 1,316 — — Money market funds 10,153 10,153 — — Total assets $ 11,469 $ 11,469 — — Warrant liability $ 3,872 — — $ 3,872 Total liabilities $ 3,872 — — $ 3,872 March 31, 2018 Cash on deposit $ 376 $ 376 — — Restricted cash 328 328 — — Money market funds 26,847 26,847 — — Total assets $ 27,551 $ 27,551 — — Warrant liabilities $ 9,299 — — $ 9,299 Total liabilities $ 9,299 — — $ 9,299 The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. Level 3 financial liabilities consist of the warrant liability for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The Company uses the Black-Scholes option valuation model to value the Level 3 warrant liability at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as volatility. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Balance - January 1, 2018 $ 3,872 March 2018 Public Offering - Series 1 Warrants 3,481 March 2018 Public Offering - Series 2 Warrants 5,500 Gain adjustment to fair value (3,554 ) Balance - March 31, 2018 $ 9,299

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents held with one bank which exceed FDIC insured limits and certain short-term investments. Ongoing credit evaluations of the customer’s financial condition are performed and independent credit ratings for the associated counterparties are reviewed by the Company and collateral is not required. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any losses in such account.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents. The Company's cash and cash equivalents include cash on deposit and a money market fund. The Company reported cash, cash equivalents, and restricted cash of $27.6 million as of March 31, 2018. See Note 7 for further details on the nature of the restricted cash.
Short-Term Investments	Short-Term Investments The Company's held-to-maturity investments in U.S. government securities, commercial paper, and its overnight repurchase agreement are carried at amortized cost and any premiums or discounts are amortized or accreted through the maturity date of the investment. Any impairment that is not deemed to be temporary is recognized in the period identified.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are expenses directly related to the Form S-3 filed with the SEC on October 30, 2015 and declared effective on November 16, 2015. These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the Shelf Registration. Deferred costs associated with the Shelf Registration are reclassified to additional paid in capital on a pro-rata basis when the Company completes offerings under the Shelf Registration, with any remaining deferred offering costs to be charged to the results of operations at the end of the three-year life of the Shelf Registration.
Warrant Liabilities	Warrant Liabilities On June 21, 2016, the Company sold an aggregate of 9,375,000 shares of common stock and warrants (the “June 2016 Public Offering”) to purchase up to 4,218,750 shares of the Company's common stock under the Shelf Registration at a public offering price of $2.40 per share of common stock sold. On March 8, 2018, the Company sold 17,751,500 shares of its common stock and warrants to purchase up to 21,301,800 shares of the Company’s common stock under the Shelf Registration at a public offering price of $1.69 per share of common stock sold. The Company accounted for these warrants as liabilities measured at fair value. The fair values of these warrants have been determined using the Black-Scholes valuation model ("Black-Scholes"). The warrants are subject to remeasurement at each balance sheet date, using Black-Scholes, with any changes in the fair value of the outstanding warrants recognized in the accompanying statements of operation.
Comprehensive Loss	Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue The Company has entered into arrangements involving the sale or license of intellectual property and the provision of other services. When entering into any arrangement involving the sale or license of intellectual property rights and other services, the Company determines whether the arrangement is subject to accounting guidance in ASC 606, Revenue from Contracts with Customers Collaborative Arrangements Analyzing the arrangement to identify performance obligations requires the use of judgment. In arrangements that include the sale or license of intellectual property and other promised services, the Company first identifies if the licenses are distinct from the other promises in the arrangement. If the license is not distinct, the license is combined with other services into a single performance obligation. Factors that are considered in evaluating whether a license is distinct from other promised services include, for example, whether the counterparty can benefit from the license without the promised service on its own or with other readily available resources and whether the promised service is expected to significantly modify or customize the intellectual property. The Company classifies non-refundable upfront payments, milestone payments and royalties received for the sale or license of intellectual property as revenues within its statements of operations because the Company views such activities as being central to its business operations. For the sale of intellectual property that is distinct, fixed consideration and variable consideration are included in the transaction price and recognized in revenue immediately to the extent that it is probable that there would not be a significant reversal of cumulative revenue in the future. For the license of intellectual property that is distinct, fixed and variable consideration (to the extent there will not be a significant reversal in the future) are also recognized immediately in income, except for consideration received in the form of royalty or sales-based milestones, which is recorded when the customer’s subsequent sales or usages occur. If the sale or license of intellectual property is not distinct, revenue is deferred and recognized over the estimated period of the Company’s combined performance obligation. For contractual arrangements that meet the definition of a collaborative arrangement under Topic 808, consideration received for any units-of-account that are outside the scope of Topic 606 are recognized in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company's August 2013 development, license, and supply agreement with R-Pharm, CJSC (“R-Pharm”), combined with the supplemental arrangement in November 2014 (the “R-Pharm Agreement”), is a collaborative arrangement pursuant to Topic 808. The Company received a non-refundable upfront payment of $1.5 million from R-Pharm in August 2013 which is being recognized over the estimated relationship period of 70 months for the combined performance obligation that includes the license of intellectual property and the participation on a joint steering committee. The Company recognized revenue from this upfront payment of $0.1 million for the three months ended March 31, 2018 and 2017. The Company is entitled to receive other payments under the R-Pharm Agreement including development and sales-based milestones and royalties; however, the variable consideration was fully constrained as of March 31, 2018. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. The Company recorded receivables for unpaid reimbursement amounts due from R-Pharm of $0.3 million as of March 31, 2018 and December 31, 2017, which are presented in prepaid expenses and other current assets in the accompanying balance sheets. In July 2016, the Company entered into an Asset Purchase agreement with UK-based Cypralis Limited (or "Cypralis"), a life sciences company, for the sale of its cyclophilin inhibitor assets. Cypralis also acquired all patents, patent applications and know-how related to the acquired portfolio. In connection with the Asset Purchase agreement, the Company is eligible to receive milestone payments upon the successful progression of Cypralis clinical candidates into later stage clinical studies and royalties payable upon product commercialization. The Company retains the right to repurchase the portfolio assets from Cypralis if abandoned or deprioritized. For the three months ended March 31, 2018, there was no revenue recognized associated with this agreement given the variable consideration associated with the sale of intellectual property to Cypralis was fully constrained as of March 31, 2018. Additionally, in October 2014 we entered into a license agreement with Waterstone Pharmaceutical HK Limited (or “Waterstone”) and granted Waterstone an exclusive, worldwide license to develop and commercialize certain non-strategic compounds. The Company is entitled to receive potential milestones and royalties from Waterstone and for the three months ended March 31, 2018, there was no revenue recognized by the Company associated with this agreement.
Research and Development	Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Information about the Company’s gross research and development expenses and the reimbursements due under the collaboration arrangement with R-Pharm for the three months ended March 31, 2018 and 2017, is presented as follows (in thousands): Three Months Ended March 31, 2018 2017 Research and development expense, gross $ 5,326 $ 4,039 Less: Reimbursement of research and development expense — 19 Research and development expense, net of reimbursements $ 5,326 $ 4,020
Patent Expense	Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Amortization of Debt Discount	Amortization of Debt Discount The Company's term loan in the amount of $15.0 million (the “Term Loan”) with Solar Capital Ltd. (“Solar”) is recorded net of debt discount which comprised issuance costs, customary closing and final fees, and the fair value of the warrants issued in conjunction with the Term Loan (Note 8). The resulting debt discount is being amortized over the term of the Term Loan using the straight-line method, which approximates the effective interest method, and the amortization of debt discount is included in the accompanying statements of operations.
Income Taxes	Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. Certain modifications made to an outstanding incentive stock option award at any time after the initial grant dates which are considered to be “material modifications”, as defined within the Internal Revenue Code, may result in the affected award being recharacterized as a non-statutory stock option. The effects of any recharacterization modification for purposes of income tax accounting are recognized on a prospective basis.
Share-based Compensation	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the award is recorded as expense over the requisite service periods and the Company recognizes forfeitures as they occur in the period.
Basic and Diluted Net Loss per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases, or ASU 2016-02. The new guidance requires lessees to recognize the assets and liabilities arising from leases on the balance sheet. For public companies, ASU 2016-02 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the impact that the implementation of ASU 2016-02 will have on the Company’s financial statements.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Research and Development Expenses and Reimbursements Due	Information about the Company’s gross research and development expenses and the reimbursements due under the collaboration arrangement with R-Pharm for the three months ended March 31, 2018 and 2017, is presented as follows (in thousands): Three Months Ended March 31, 2018 2017 Research and development expense, gross $ 5,326 $ 4,039 Less: Reimbursement of research and development expense — 19 Research and development expense, net of reimbursements $ 5,326 $ 4,020
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. March 31, 2018 2017 Warrants to purchase Series C-1 Preferred 14,033 14,033 Warrants to purchase common stock associated with Loan Agreement 122,435 122,435 Warrants to purchase common stock associated with June 2016 Public Offering 4,218,750 — Warrants to purchase common stock associated with March 2018 Public Offering - Series 1 13,313,625 — Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 7,988,175 — Stock options 4,152,734 2,770,029

Short-term Investments (Tables)

Short-term Investments (Tables)	3 Months Ended
	Mar. 31, 2018
Investments Debt And Equity Securities [Abstract]
Held-to-maturity Securities	The following table summarizes the held-to-maturity securities held at March 31, 2018 (in thousands): Amortized Cost Unrealized Gains Unrealized Losses Fair Value As of March 31, 2018 U.S. government securities $ 10,990 $ 5 $ (6 ) $ 10,989 Commercial paper 7,487 — — 7,487 Overnight repurchase agreement 18,000 — — 18,000 Total short-term investments $ 36,477 $ 5 $ (6 ) $ 36,476

Prepaid Expenses and Other Cu19

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2018
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): March 31, 2018 December 31, 2017 Prepaid SCY-078 development services $ 48 $ 384 Prepaid insurance 96 279 Other prepaid expenses 158 62 Other receivable due from R-Pharm 251 251 Other current assets 92 91 Total prepaid expenses and other current assets $ 645 $ 1,067

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2018
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following (in thousands): March 31, 2018 December 31, 2017 Accrued research and development expenses $ 355 $ 609 Accrued employee bonus compensation 261 763 Employee withholdings 32 29 Other accrued expenses 289 304 Total accrued expenses $ 937 $ 1,705

Borrowings (Tables)

Borrowings (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Schedule of Future Principal Debt Payments	Future principal debt payments on the currently outstanding Term Loan payable as of March 31, 2018 are as follows (in thousands): 2018 $ 1,875 2019 7,500 2020 5,625 Total principal payments 15,000 Final fee due at maturity 780 Total principal and final fee payment 15,780 Unamortized discount and debt issuance costs (1,017 ) Less current portion (3,599 ) Loan payable, long term $ 11,164

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments for all operating leases as of March 31, 2018 are as follows (in thousands): 2018 $ 510 2019 498 2020 508 2021 518 2022 529 Thereafter 4,919 Total $ 7,482

Stockholder's Equity (Tables)

Stockholder's Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Summary of Common Stock Shares Activity	The following table summarizes common stock share activity for the three months ended March 31, 2018 (dollars in thousands): Shares of Common Stock Common Stock Additional Paid-in Capital Accumulated Deficit Total Stockholders' Equity Balance, December 31, 2017 28,971,651 $ 29 $ 226,631 $ (205,250 ) $ 21,410 Net loss — — — (4,002 ) (4,002 ) Stock-based compensation expense — — 425 — 425 Common stock issued through employee stock purchase plan 13,591 — 20 — 20 Common stock issued under Shelf Registration, net of expenses 17,852,193 18 18,980 — 18,998 Common stock issued for vested restricted stock units 6,006 — (7 ) — (7 ) Balance, March 31, 2018 46,843,441 $ 47 $ 246,049 $ (209,252 ) $ 36,844
Common Stock Reserved For Future Issuances	The Company had reserved shares of common stock for future issuance as follows: March 31, 2018 December 31, 2017 Outstanding stock options 4,152,734 3,075,994 Outstanding Series C-1 Preferred warrants 14,033 14,033 Warrants to purchase common stock associated with June 2016 Public Offering 4,218,750 4,218,750 Warrants to purchase common stock associated with March 2018 Public Offering - Series 1 13,313,625 — Warrants to purchase common stock associated with March 2018 Public Offering - Series 2 7,988,175 — Warrants to purchase common stock associated with Loan Agreement 122,435 122,435 For possible future issuance under 2014 Equity Incentive Plan (Note 9) 528,197 492,382 For possible future issuance under Employee Stock Purchase Plan (Note 9) 99,437 83,617 For possible future issuance under 2015 Inducement Plan (Note 9) 5,000 5,000 Total common shares reserved for future issuance 30,442,386 8,012,211

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	The activity for the 2009 Stock Option Plan, 2014 Plan and 2015 Plan for the three months ended March 31, 2018, is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value ($000) Outstanding — January 1, 2018 3,075,994 $ 5.59 7.23 $ 151 Granted 1,111,470 $ 1.76 Exercised — $ — Forfeited/Cancelled (34,730 ) $ 4.53 Outstanding — March 31, 2018 4,152,734 $ 4.57 7.68 $ — Exercisable — March 31, 2018 1,859,894 $ 6.73 5.87 $ — Vested or expected to vest — March 31, 2018 4,152,734 $ 4.57 7.68 $ — Restricted stock unit ("RSU") activity under the 2014 Plan for the three months ended March 31, 2018, is summarized as follows: Number of Shares Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2017 64,365 $ 2.70 Granted 51,550 $ 1.69 Vested (9,701 ) $ 3.11 Forfeited/Cancelled (5,239 ) $ 3.02 Non-vested at March 31, 2018 100,975 $ 2.13
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations (in thousands): Three Months Ended March 31, 2018 2017 Research and development $ 108 $ 94 Selling, general and administrative 317 302 Total $ 425 $ 396

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured on a Recurring Basis	The following table summarizes the conclusions reached as of March 31, 2018 and December 31, 2017 for financial instruments measured at fair value on a recurring basis (in thousands): Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) December 31, 2017 Cash on deposit $ 1,316 $ 1,316 — — Money market funds 10,153 10,153 — — Total assets $ 11,469 $ 11,469 — — Warrant liability $ 3,872 — — $ 3,872 Total liabilities $ 3,872 — — $ 3,872 March 31, 2018 Cash on deposit $ 376 $ 376 — — Restricted cash 328 328 — — Money market funds 26,847 26,847 — — Total assets $ 27,551 $ 27,551 — — Warrant liabilities $ 9,299 — — $ 9,299 Total liabilities $ 9,299 — — $ 9,299
Reconciliation of liabilities using level 3 inputs	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows (in thousands): Balance - January 1, 2018 $ 3,872 March 2018 Public Offering - Series 1 Warrants 3,481 March 2018 Public Offering - Series 2 Warrants 5,500 Gain adjustment to fair value (3,554 ) Balance - March 31, 2018 $ 9,299

Description of Business and B26

Description of Business and Basis of Preparation - Additional Information (Detail) - USD ($)	Mar. 08, 2018	Nov. 16, 2015	Mar. 31, 2018	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity offering price		$ 150,000,000
Common stock issued under Shelf Registration, net of expenses (in shares)	17,751,500
Number of warrants issued to purchase common stock (in shares)			14,033	14,033
Net proceeds from the June 2016 Public Offering			$ 18,998,000
Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock issued under Shelf Registration, net of expenses (in shares)			17,852,193
Net proceeds from the June 2016 Public Offering			$ 18,000
Sales Agreement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration share issued pursuant to warrant sold			52,500,000
Remaining amount of common stock in pursuant to shelf registration			23,900,000
Remaining amount of other allowable securities in pursuant to shelf registration			$ 28,200,000
Shelf registration expiration date			Nov. 16, 2018
Sales Agreement | Common Stock
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Shelf registration maximum equity offering price		$ 40,000,000
March 2018 Public Offering
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock issued under Shelf Registration, net of expenses (in shares)	17,751,500
Number of warrants issued to purchase common stock (in shares)	21,301,800
Share price (in dollars per share)	$ 1.69
Net proceeds from the June 2016 Public Offering	$ 27,900,000

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Additional Information (Detail)	Mar. 08, 2018$ / sharesshares	Jun. 21, 2016$ / sharesshares	Aug. 31, 2013USD ($)	Mar. 31, 2018USD ($)bankshares	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)
Subsidiary, Sale of Stock [Line Items]
Cash, cash equivalents, and restricted cash | $				$ 27,551,000	$ 19,908,000	$ 11,469,000	$ 35,656,000
Common stock issued under Shelf Registration, net of expenses (in shares)	17,751,500
Number of warrants issued to purchase common stock (in shares)				14,033		14,033
Upfront payment received | $			$ 1,500,000
Deferred revenue estimated performance period			70 months
Revenue recognized from upfront payments | $				$ 100,000	$ 100,000
Other receivable due from R-Pharm | $				$ 251,000		$ 251,000
Secured Debt | Term Loan
Subsidiary, Sale of Stock [Line Items]
Term loan, face amount | $								$ 15,000,000
June 2016 Public Offering
Subsidiary, Sale of Stock [Line Items]
Common stock issued under Shelf Registration, net of expenses (in shares)		9,375,000
Number of warrants issued to purchase common stock (in shares)		4,218,750
Share price (in dollars per share) | $ / shares		$ 2.40
March 2018 Public Offering
Subsidiary, Sale of Stock [Line Items]
Common stock issued under Shelf Registration, net of expenses (in shares)	17,751,500
Number of warrants issued to purchase common stock (in shares)	21,301,800
Share price (in dollars per share) | $ / shares	$ 1.69
Banking Concentration Risk [Member]
Subsidiary, Sale of Stock [Line Items]
Number of banks | bank				1

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Schedule of Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Research and development expense, gross	$ 5,326	$ 4,039
Less: Reimbursement of research and development expense	0	19
Research and development expense, net of reimbursements	$ 5,326	$ 4,020

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Shares (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	4,152,734	2,770,029
Warrants to purchase Series C-1 Preferred | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	14,033	14,033
Warrants to purchase common stock associated with Loan Agreement | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	122,435	122,435
Warrants to purchase common stock associated with June 2016 Public Offering | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	4,218,750
March 2018 Public Offering Series 1 [Member] | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	13,313,625
March 2018 Public Offering Series 2 [Member] | Warrant liability
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	7,988,175

Short-term Investments (Details

Short-term Investments (Details) $ in Thousands	Mar. 31, 2018USD ($)
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	$ 36,477
Unrealized Gains	5
Unrealized Losses	(6)
Fair Value	36,476
U.S. government securities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	10,990
Unrealized Gains	5
Unrealized Losses	(6)
Fair Value	10,989
Commercial paper
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	7,487
Fair Value	7,487
Overnight repurchase agreement
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	18,000
Fair Value	$ 18,000

Prepaid Expenses and Other Cu31

Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Abstract]
Prepaid SCY-078 development services	$ 48	$ 384
Prepaid insurance	96	279
Other prepaid expenses	158	62
Other receivable due from R-Pharm	251	251
Other current assets	92	91
Total prepaid expenses and other current assets	$ 645	$ 1,067

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Payables And Accruals [Abstract]
Accrued research and development expenses	$ 355	$ 609
Accrued employee bonus compensation	261	763
Employee withholdings	32	29
Other accrued expenses	289	304
Total accrued expenses	$ 937	$ 1,705

Borrowings - Additional Informa

Borrowings - Additional Information (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Number of warrants issued to purchase common stock (in shares)		14,033	14,033
Warrants to purchase common stock associated with Loan Agreement
Debt Instrument [Line Items]
Number of warrants issued to purchase common stock (in shares)	122,435	122,435
Exercise price of warrants (in dollars per share)	$ 3.6754	$ 3.6754
Warrants issued, expiration period	5 years	5 years
Secured Debt | Term Loan
Debt Instrument [Line Items]
Loan agreement term	48 months
Term loan, face amount	$ 15,000,000
Loan agreement maturity date		Sep. 30, 2020
Increase in final fee payable at Maturity Date		$ 30,000
Interest only payment expiration date		Oct. 1, 2018
Secured Debt | Term Loan | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)	8.49%

Borrowings - Schedule of Future

Borrowings - Schedule of Future Principal Debt Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Less current portion	$ (3,599)	$ (4,349)
Secured Debt | Term Loan
Debt Instrument [Line Items]
2,018	1,875
2,019	7,500
2,020	5,625
Total principal payments	15,000
Final fee due at maturity	780
Total principal and final fee payment	15,780
Unamortized discount and debt issuance costs	(1,017)
Less current portion	(3,599)
Loan payable, long term	$ 11,164

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Mar. 01, 2018USD ($)ft²	Jul. 22, 2015USD ($)ft²	Mar. 31, 2018USD ($)Agreement	Mar. 31, 2017USD ($)
Commitment And Contingencies [Line Items]
Long-term lease agreement, area of office space | ft²	19,275
Lease term	11 years
Total lease payments	$ 7,300,000
Renewal term	5 years
Renewal term, description	The Company has the option to renew for two consecutive five-year periods from the end of the first term. Under the lease, the Company must furnish a security deposit in the form of a standby letter of credit in the amount of $0.3 million, which will be reduced by fifty-five thousand dollars every two years for ten years after the commencement of the lease
Security deposit in the form of a standby letter of credit	$ 300,000
Decrease in security deposit	55,000
Number of additional license agreements | Agreement			2
License agreements fee			$ 2,300,000
Maximum
Commitment And Contingencies [Line Items]
Renovation cost	$ 1,300,000
Milestone payments from the Company			19,000,000
Jersey City, New Jersey
Commitment And Contingencies [Line Items]
Area of subleased space (in sqft) | ft²		10,141
Base rent, per month		$ 25,000
Annual increase in base rent (percent)		3.00%
Security deposit paid		$ 100,000
Rent expense			$ 100,000	$ 100,000

Commitments and Contingencies36

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands	Mar. 31, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,018	$ 510
2,019	498
2,020	508
2,021	518
2,022	529
Thereafter	4,919
Total	$ 7,482

Stockholder's Equity - Addition

Stockholder's Equity - Additional Information (Detail) - USD ($)	Mar. 08, 2018	Sep. 30, 2016	Jun. 21, 2016	Jul. 31, 2006	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Schedule Of Capitalization Equity [Line Items]
Common stock, par value (in dollars per share)					$ 0.001		$ 0.001
Common stock, shares authorized (in shares)					125,000,000		125,000,000
Common stock, shares issued (in shares)					46,843,441		28,971,651
Common stock, shares outstanding (in shares)					46,843,441		28,971,651
Number of warrants issued to purchase common stock (in shares)					14,033		14,033
Common stock issued under Shelf Registration, net of expenses (in shares)	17,751,500
Warrant liabilities fair value adjustment					$ (3,554,000)	$ (1,523,000)
Warrant liabilities					$ 9,300,000
Warrants to purchase common stock associated with Loan Agreement
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)		122,435			122,435
Exercise price of warrants (in dollars per share)		$ 3.6754			$ 3.6754
Warrant expiration period		5 years			5 years
Series 2 Warrant
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants (in dollars per share)	$ 2
Warrant term	5 years
June 2016 Public Offering
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)			4,218,750
Exercise price of warrants (in dollars per share)			$ 3
Number of shares received per warrant (in shares)			0.45
Warrant expiration period			5 years
Common stock issued under Shelf Registration, net of expenses (in shares)			9,375,000
March 2018 Public Offering
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)	21,301,800
Common stock issued under Shelf Registration, net of expenses (in shares)	17,751,500
March 2018 Public Offering | Warrant liability | Maximum
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)	21,301,800
March 2018 Public Offering | Series 1 Warrant
Schedule Of Capitalization Equity [Line Items]
Exercise price of warrants (in dollars per share)	$ 1.85
Number of shares received per warrant (in shares)	0.75
Warrant term	371 days
March 2018 Public Offering | Series 1 Warrant | Maximum
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)	13,313,625
March 2018 Public Offering | Series 2 Warrant
Schedule Of Capitalization Equity [Line Items]
Number of shares received per warrant (in shares)	0.45
March 2018 Public Offering | Series 2 Warrant | Maximum
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)	7,988,175
Series C-1 Convertible Preferred Stock [Member]
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)				196,923
Exercise price of warrants (in dollars per share)				$ 3.25
Fair value of warrants				$ 500,000
Derivative Liability					$ 0		$ 0
Common Stock
Schedule Of Capitalization Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)				14,033
Exercise price of warrants (in dollars per share)				$ 45.61

Stockholder's Equity - Summary

Stockholder's Equity - Summary of Common Stock Shares Activity (Detail) - USD ($) $ in Thousands	Mar. 08, 2018	Mar. 31, 2018	Mar. 31, 2017
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance		$ 21,410
Beginning balance (in shares)		28,971,651
Net loss		$ (4,002)	$ (4,869)
Stock-based compensation expense		425
Common stock issued through employee stock purchase plan		20
Stock issued		18,998
Stock issued (in shares)	17,751,500
Common stock issued for vested restricted stock units		(7)
Ending balance		$ 36,844
Ending balance (in shares)		46,843,441
Common Stock
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance		$ 29
Beginning balance (in shares)		28,971,651
Common stock issued through employee stock purchase plan (in shares)		13,591
Stock issued		$ 18
Stock issued (in shares)		17,852,193
Common stock issued for vested restricted stock units (in shares)		6,006
Ending balance		$ 47
Ending balance (in shares)		46,843,441
Additional Paid-in Capital
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance		$ 226,631
Stock-based compensation expense		425
Common stock issued through employee stock purchase plan		20
Stock issued		18,980
Common stock issued for vested restricted stock units		(7)
Ending balance		246,049
Accumulated Deficit
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning balance		(205,250)
Net loss		(4,002)
Ending balance		$ (209,252)

Stockholder's Equity - Schedule

Stockholder's Equity - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2016
Class of Stock [Line Items]
Outstanding stock options	4,152,734	3,075,994
Outstanding Series C-1 Preferred warrants	14,033	14,033
Total common shares reserved for future issuance	30,442,386	8,012,211
2014 Equity Incentive Plan
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (in shares)	528,197	492,382
2014 Employee Stock Purchase Plan
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (in shares)	99,437	83,617
2015 Inducement Plan
Class of Stock [Line Items]
Possible future issuance under equity compensation plan (in shares)	5,000	5,000
June 2016 Public Offering
Class of Stock [Line Items]
Outstanding Underwriting Agreement warrants	4,218,750	4,218,750
March 2018 Public Offering | Series 1 Warrant
Class of Stock [Line Items]
Outstanding Underwriting Agreement warrants	13,313,625
March 2018 Public Offering | Series 2 Warrant
Class of Stock [Line Items]
Outstanding Underwriting Agreement warrants	7,988,175
Warrants to purchase common stock associated with Loan Agreement
Class of Stock [Line Items]
Outstanding Series C-1 Preferred warrants	122,435		122,435
Outstanding Underwriting Agreement warrants	122,435	122,435

Stock-based Compensation - 2009

Stock-based Compensation - 2009 Stock Option Plan (Details) - 2009 Stock Option Plan	3 Months Ended
	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	100.00%
Vesting period of options	3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	110.00%
Vesting period of options	4 years

Stock-based Compensation - 2014

Stock-based Compensation - 2014 Equity Incentive Plan (Details) - 2014 Equity Incentive Plan - shares	May 02, 2014	Mar. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional awards expected to be granted (in shares)	0
Expiration period of options		10 years
Common stock outstanding percentage	4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares)	0
Share-based compensation arrangement by share-based payment award, number of additional shares authorized		1,158,866	984,376
Possible future issuance under equity compensation plan (in shares)		528,197	492,382
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options		3 years
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of options		4 years
Base number of new shares available for future issuance under equity incentive plan (in shares)	1,122,731
Common stock issuable period	10 years

Stock-based Compensation - 2015

Stock-based Compensation - 2015 Inducement Plan (Details) - 2015 Inducement Plan - shares	Mar. 31, 2018	Dec. 31, 2017	Mar. 26, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under the plan (in shares)			450,000
Possible future issuance under equity compensation plan (in shares)	5,000	5,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Number of Shares
Beginning balance - Outstanding (shares)	3,075,994
Granted (shares)	1,111,470
Exercised (shares)	0
Forfeited/Cancelled(shares)	(34,730)
Ending balance - Outstanding (shares)	4,152,734	3,075,994
Exercisable (shares)	1,859,894
Vested or expected to vest (shares)	4,152,734
Weighted- Average Exercise Price
Beginning balance - Outstanding (in dollars per share)	$ 5.59
Granted (in dollars per share)	1.76
Exercised (in dollars per share)	0
Forfeited/Cancelled (in dollars per share)	4.53
Ending balance - Outstanding (in dollars per share)	4.57	$ 5.59
Exercisable (in dollars per share)	6.73
Vested or expected to vest (in dollars per share)	$ 4.57
Weighted- Average Remaining Contractual Life (in years)
Balance - Outstanding	7 years 8 months 5 days	7 years 2 months 23 days
Exercisable	5 years 10 months 14 days
Vested or expected to vest	7 years 8 months 5 days
Aggregate Intrinsic Value ($000)
Balance - Outstanding	$ 0	$ 151
Exercisable	0
Vested and expected to vest	$ 0

Stock-based Compensation - RSU

Stock-based Compensation - RSU Activity (Details) - RSUs	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Number of Shares
Beginning balance - Outstanding (shares) | shares	64,365
Options granted in period (shares) | shares	51,550
Vested (shares) | shares	(9,701)
Forfeited/Cancelled (shares) | shares	(5,239)
Ending balance - Outstanding (shares) | shares	100,975
Weighted Average Grant Date Fair Value Per Share
Beginning balance - Outstanding (in dollars per share) | $ / shares	$ 2.70
Granted (in dollars per share) | $ / shares	1.69
Vested (in dollars per share) | $ / shares	3.11
Forfeited/Cancelled dollars per share) | $ / shares	3.02
Ending balance - Outstanding (in dollars per share) | $ / shares	$ 2.13
Vesting percentage	25.00%
Vesting period of options	4 years

Stock-based Compensation - 2045

Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) - 2014 Employee Stock Purchase Plan - shares	May 02, 2014	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
For possible future issuance under employee stock purchase plan (in shares)	47,794
Common stock issuable period	10 years
Common stock outstanding percentage	0.80%
Employee stock purchase plan, number of shares, which might be added to common stock outstanding (in shares)	29,411
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares)	0
Share-based compensation arrangement by share-based payment award, number of additional shares authorized		29,411	29,411
Common stock issued through employee stock purchase plan (in shares)		13,591	7,667
Possible future issuance under equity compensation plan (in shares)		99,437		83,617

Stock-based Compensation - Comp

Stock-based Compensation - Compensation Cost (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based compensation expense	$ 425,000	$ 396,000
Tax benefit from compensation expense	0	0
Cash received from option exercised	$ 0	$ 0

Stock-based Compensation - Expe

Stock-based Compensation - Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 425	$ 396
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	108	94
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 317	$ 302

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Instruments Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	$ 27,551	$ 11,469
Fair value of financial liabilities	9,299	3,872
Restricted cash	328
Warrant liability
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	9,299	3,872
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	27,551	11,469
Restricted cash	328
Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	9,299	3,872
Significant Unobservable Inputs (Level 3) | Warrant liability
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial liabilities	9,299	3,872
Cash on deposit
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	376	1,316
Cash on deposit | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	376	1,316
Money market funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	26,847	10,153
Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Fair value of financial assets	$ 26,847	$ 10,153

Fair Value Measurements - Sum49

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 3,872
Gain adjustment to fair value	(3,554)
Ending balance	9,299
Series 1 | Warrant liability
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
March 2018 Public Offering	3,481
Series 2 | Warrant liability
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
March 2018 Public Offering	$ 5,500